NCA
RCUS icon

New Century Advisors’s Arcus Biosciences RCUS Stock Holding History

New Century Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$8K Buy
+288
New +$7.62K 0.01% 97

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

New Century Advisors's RCUS Position: Q3 2022 in Review

New Century Advisors opened a new position in Arcus Biosciences (RCUS) in Q3 2022: 288 shares worth $8K. The stake represents 0.01% of the portfolio and ranks #97 among its holdings.

184 funds tracked by Wall St. Rank hold RCUS as of Q3 2022.

  • New Century Advisors held 288 shares of Arcus Biosciences worth $8K as of Q3 2022.
  • Arcus Biosciences was a new New Century Advisors position in Q3 2022.
  • Arcus Biosciences made up 0.01% of New Century Advisors's portfolio in Q3 2022, its #97 holding.
  • 184 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2022.

Based on New Century Advisors's 13F filing for Q3 2022, filed 13 Oct 2022.